Fondaparinux is currently approved for use in the EU for the prevention of venous thromboembolic events (VTE), initial treatment of acute deep vein thrombosis
(DVT), pulmonary embolism (PE) treatment of unstable angina or non-ST segment elevation myocardial infarction (UA/NSTEMI) and for the treatment of ST segment elevation myocardial infarction (STEMI).
Early mobilization in patients with acute deep vein thrombosis
: does it increase the incidence of symptomatic pulmonary embolism?
Acute deep vein thrombosis
: Early mobilization does not increase the frequency of pulmonary embolism.
Pregnant women were hospitalized for an average of 6.4 days to treat acute deep vein thrombosis
, and postpartum women were hospitalized for an average of 9.1 days.
Ruling out acute deep vein thrombosis
by ELISA plasma D-dimer assay versus ultrasound in inpatients more than 70 years old.
Boehringer Ingelheim today announced the submission of an application to the European Medicines Agency (EMA) for use of Pradaxa (dabigatran etexilate) for the treatment of acute deep vein thrombosis
(DVT) and pulmonary embolism (PE) and the prevention of recurrent DVT and PE.
In the trial, 1,240 patients with acute deep vein thrombosis
received ximelagatran (36 mg twice daily) and 1,249 patients received standard therapy with enoxaparin for 5 days followed by warfarin for 6 months.